p53 mutation in histologically normal mucosa of the aero-digestive tract is not a marker of increased risk for second primary carcinoma in head and neck cancer patients

  • Anette EscherEmail author
  • Elsa Piotet
  • Francois Waridel
  • Richard Iggo
  • Philippe Monnier
Head and Neck


Head and neck cancer patients are at high risk for developing second primary tumors. This is known as field cancerization of the aero-digestive tract. In a previous study, we showed that patients with multiple primary tumors were more likely to have p53 mutations in histologically normal mucosae than patients presenting with an isolated tumor. Based on this observation, we postulated that p53 mutations in normal tissue samples of patients bearing a single primary tumor could have a clinical value as a biomarker for the risk of developing second primary tumors. Thirty-five patients presenting with a single primary tumor were followed-up for a median of 51 months (range 1 month to 10.9 years) after biopsies of histologically normal squamous cell mucosa had been analyzed for p53 mutations with a yeast functional assay at the time of the primary tumor. During this follow-up, recurrences and non-sterilization of the primary tumor, occurrence of lymph node metastases, and of second primary tumors were evaluated. Sixteen (45.7%) patients were found to have p53 mutations in their normal squamous cell mucosa, and 19 (54.3%) patients showed no mutation. No relationship was found between p53 mutations and the occurrence of evaluated events during follow-up. Notably, the rate of second primary tumors was not associated with p53 mutations in the normal squamous mucosa. The correlation between p53 mutations in histologically normal mucosae and the incidence of second primary tumors is generally low. The benefit of analyzing p53 mutations in samples of normal squamous cell mucosa in every patient with a primary tumor of the head and neck is doubtful.


Head and neck cancer Second primary tumor p53 Field cancerization 


  1. 1.
    Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10–30PubMedCrossRefGoogle Scholar
  2. 2.
    Leon X, Quer M, Diez S, Orus C, Lopez-Pousa A, Burgues J (1999) Second neoplasm in patients with head and neck cancer. Head Neck 21:204–210PubMedCrossRefGoogle Scholar
  3. 3.
    Khuri FR, Kim ES, Lee JJ, Winn RJ, Brenner SE, Lippman SM, Fu KK, Cooper JS, Vokes EE, Chamberlain RM, Williams B, Pajak TF, Goepfert H, Hong WK (2001) The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev 10:823–829PubMedGoogle Scholar
  4. 4.
    Slaughter DP, Southwick HW, Sejkal W (1953) Field cancerization in oral stratified squamous epithelium, clinical implication of multicentric origin. Cancer 6:963–968PubMedCrossRefGoogle Scholar
  5. 5.
    Vokes EE, Weichselbaum RR, Lippman SM, Hong WK (1993) Head and neck cancer. N Engl J Med 328:184–194PubMedCrossRefGoogle Scholar
  6. 6.
    Savary M, Monnier P, Pasche R, Brossard E, Pasche P, Lang F (1991) Multiple primary malignancies. Adv Otorhinolaryngol 46:165–175PubMedGoogle Scholar
  7. 7.
    Field JK (1995) The role of oncogenes and tumour-suppressor genes in the aetilogy of oral, head and neck squamous cell carcinoma. J R Soc Med 88:35–39Google Scholar
  8. 8.
    Harris CC, Hollstein M (1993) Clinical implcations of the p 53 tumor suppressor-gene. N Engl J Med 329:1318–1327PubMedCrossRefGoogle Scholar
  9. 9.
    Waridel F, Iggo R (1996) Identification of clonal mutations in morphologically normal mucosa of the aero-digestive tract. Eur J Cancer Prev 5(Suppl 2):67–73PubMedCrossRefGoogle Scholar
  10. 10.
    Waridel F, Estreicher A, Bron L, Flaman J-M, Fontolliet C, Monnier P, Frebourg T, Iggo R (1997) Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract. Oncogene 14:163–169PubMedCrossRefGoogle Scholar
  11. 11.
    Harrington DP, Fleming TR (1982) A class of rank test procedures for censored survival data. Biometrika 69:553–566CrossRefGoogle Scholar
  12. 12.
    Ikhaka R, Gentleman RR (1996) A language for data analysis and graphics. J Comput Graph Stat 5:299–314CrossRefGoogle Scholar
  13. 13.
    Tabor MP, Brakenhoff RH, van Houten VM, Kummer JA, Snnel MH, Snijders PJ, Snow GB, Leemans CR, Braakhuis BJ (2001) Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin Cancer Res 7:1523–1532PubMedGoogle Scholar
  14. 14.
    Homann N, Nees M, Conradt C, Dietz A, Weidauer H, Maier H, Bosch FX (2001) Overexpression of p53 in tumor-distant epithelia of head and neck cancer patients is associated with an increased incidence of second primary carcinoma. Clin Cancer Res 7:290–296PubMedGoogle Scholar
  15. 15.
    Partridge M, Li SR, Pateromichelakis S, Francis R, Phillips E, Huang XH, Tesfa-Selase F, Langdon JD (2000) Detection of minimal residual cancer to investigate why oral tumors recur despite seemingly adequate treatment. Clin Cancer Res 6:2718–2725PubMedGoogle Scholar
  16. 16.
    Sasano H, Miyazaki S, Gooukon Y, Nishihira T, Sawai T, Nagura H (1992) Expression of p53 in human esophaeal carcinoma: an immunohistochemical study with correlation to proliferating cell nuclear antigen expression. Hum Pathol 23:1238–1243PubMedCrossRefGoogle Scholar
  17. 17.
    El-Naggar AK, Lai S, Luna MA, Zhou XD, Weber RS, Goepfert H, Batsakis JG (1995) Sequential p53 mutation analysis of pre-invasive and invasive head and neck squamous carcinoma. Int J Cancer 64:196–201PubMedCrossRefGoogle Scholar
  18. 18.
    Gonzalez-Moles MA, Galindo P, Gutierrez J, Rodriguez-Archilla A, Ruiz-Avila I, Sanchez-Fernandez E (2002) Significance of p53 expression in non-tumoral epithelium adjacent to oral suaqmous cell carcinomas. J Laryngol Otol 116:355–358PubMedCrossRefGoogle Scholar
  19. 19.
    Taylor D, Koch WM, Zahurak M, Shah K, Sidransky D, Westra WH (1999) Immunohistochemical detection of p53 protein accumulation in head and neck cancer: correlation with p53 gene alterations. Hum Pathol 30:1221–1225PubMedCrossRefGoogle Scholar
  20. 20.
    Ma L, Ronai A, Riede UN, Kohler G (1998) Clinical implication of screening p53 gene mutations in head and neck squamous cell carcinomas. J Cancer Res Clin Oncol 124:389–396PubMedCrossRefGoogle Scholar
  21. 21.
    Roth JA (1999) p53 prognostication: paradigm or paradox? Clin Cancer Res 5:3345PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Anette Escher
    • 1
    Email author
  • Elsa Piotet
    • 1
  • Francois Waridel
    • 1
  • Richard Iggo
    • 2
  • Philippe Monnier
    • 1
  1. 1.Department of Otolaryngology and Head and Neck SurgeryUniversity Hospital, Centre Universitaire Hospitalier Vaudois (CHUV)LausanneSwitzerland
  2. 2.Bute Medical School, University of St AndrewsSt AndrewsUK

Personalised recommendations